Please login to the form below

Not currently logged in
Email:
Password:

Bina Rawal joins ABPI as medical, innovation and research director

Appointment comes as trade body prepares for drug pricing discussions

Bina Rawal ABPIThe Association of the British Pharmaceutical Industry (ABPI) has appointed the Wellcome Trusts' Dr Bina Rawal as medical, innovation and research director.

Dr Rawal will join the ABPI in October, 2012, at what will be a crucial time for the UK's pharma industry as it approaches discussions about the future shape of the country's drug pricing system.

She will be central to this process, serving as senior medical spokesperson for the industry trade body when dealing with government, the media and professional organisations, as well as holding responsibility for advancing the productivity of the innovation process in the UK.

“We need a strong voice for innovation in the industry and Bina's experience and background will complement that of our members' to champion science, discovery, research and development and enable it to thrive in the UK," said the ABPI's chief executive Stephen Whitehead.

During her three years at the Wellcome Trust, Dr Rawal served as head of clinical development within the research charity's technology transfer division.

In this role, she was responsible for oversight and governance of the division's clinical pipeline, derived from the funding of translational research, clinical validation work and the development of new products, including medicines and devices.

Prior to her time at the Wellcome Trust, she spent several years at Roche, including serving as therapeutic area expert in the UK, and Dr Rawal gained further big pharma experience at GlaxoWellcome, where she worked in its R&D division.

“The pharmaceutical industry plays a vital role as a healthcare provider in the UK and research and development are an integral part of the patient journey through the NHS,” said Dr Rawal.

“I am very excited about working with members, the innovation board and many stakeholders to demonstrate and enhance this contribution for the benefit of patients and the UK economy."

31st July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics